A well deserved 10% price correctionI anticipate a price correction of approximately 10%, bringing the stock price down to around $18.80. Despite this expected short-term decline, my long-term outlook remains highly positive. The company continues to be a strong profit generator, with revenue growing at an impressive pace. Its newly l
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.253 CHF
148.84 M CHF
446.59 M CHF
111.11 M
About Catalyst Pharmaceuticals, Inc.
Sector
Industry
CEO
Richard John Daly
Website
Headquarters
Coral Gables
Founded
2002
FIGI
BBG00LVDFHG9
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
CPRX Growth Stock with Favorable UpsideCatalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ): Growth Stock with Favorable Upside
Trade Setup:
- Buy Price: $21.31
- Stop-Loss: $19.31
- Take-Profit Targets:
- TP1: $25.32
- TP2: $30.22
Rationale:
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focusing on inno
The same idea....look my other postsWhile I remain long-term bullish on CPRX, the current price level seems elevated, and there are signs suggesting a pullback is imminent. The RSI indicates that the stock has been overbought, and we may see a correction soon. I'm closely watching the Fibonacci retracement at 0.618, which has proven t
Make a good decision, and realize your profit.Make a good decision, and realize your profit.
You can see my oldest ideas, I was always bullish on this stock, and I still am. On August 7 they report the second quarter, and I expect good numbers. Those who follow the company management expect the same, I think. But they are greedy, I am greedy t
Long term stock idea: CPRX (Small Cap Biotech) When markets are messy I like to explore long term bases in relatively unknown stocks.
CPRX has a 15 year base with contracting volatility in recent years, mostly since 2019.
I like the look of the quarterly chart and I like the volume markers on the daily - institutional funds have been progress
You can start to buy!It is time to buy the shares. On 28 February they will report the fourth quarter. I expect very good news, but this is irrelevant. You can see that there is a turning point in the chart. The first target is around 15.20, then it is going to refill the gap.
And of course in the long term, this short
Catalyst Pharmaceuticals Short CPRX - waiting for short position.
Market almost touched a higher Lin Reg and above MACD on D1.
Confirmation: NOT YET !!!!.
Red box: Buy area.
Suggested TP: Tp1 at $10.40(close 50% of the position) and 2nd at $5.80.
Suggested SL: Always follow the Ratio - min 1:3
Warning!!!!
This content should not
CPRX ready for a good correction. $$As per the image. Key points selling points highlighted in red.
Key reinforment poins (long) highlighted in green.
Good profit may come your way!
I still believe the full correction is yet to come. we may be taking about a couple of weeks away. But it has strong cofirmation points to watch out fo
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of CN2 is 21.659 CHF — it has increased by 7.13% in the past 24 hours. Watch CATALYST PHARMACEU stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CATALYST PHARMACEU stocks are traded under the ticker CN2.
CN2 stock hasn't changed in a week, the month change is a 7.13% rise, over the last year CATALYST PHARMACEU has showed a 45.02% increase.
We've gathered analysts' opinions on CATALYST PHARMACEU future price: according to them, CN2 price has a max estimate of 32.37 CHF and a min estimate of 25.09 CHF. Watch CN2 chart and read a more detailed CATALYST PHARMACEU stock forecast: see what analysts think of CATALYST PHARMACEU and suggest that you do with its stocks.
CN2 stock is 6.66% volatile and has beta coefficient of 0.80. Track CATALYST PHARMACEU stock price on the chart and check out the list of the most volatile stocks — is CATALYST PHARMACEU there?
Today CATALYST PHARMACEU has the market capitalization of 2.37 B, it has increased by 11.26% over the last week.
Yes, you can track CATALYST PHARMACEU financials in yearly and quarterly reports right on TradingView.
CATALYST PHARMACEU is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
CN2 earnings for the last quarter are 0.40 CHF per share, whereas the estimation was 0.31 CHF resulting in a 29.96% surprise. The estimated earnings for the next quarter are 0.30 CHF per share. See more details about CATALYST PHARMACEU earnings.
CATALYST PHARMACEU revenue for the last quarter amounts to 128.79 M CHF, despite the estimated figure of 121.85 M CHF. In the next quarter, revenue is expected to reach 116.40 M CHF.
CN2 net income for the last quarter is 50.80 M CHF, while the quarter before that showed 37.19 M CHF of net income which accounts for 36.60% change. Track more CATALYST PHARMACEU financial stats to get the full picture.
No, CN2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 28, 2025, the company has 181 employees. See our rating of the largest employees — is CATALYST PHARMACEU on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CATALYST PHARMACEU EBITDA is 211.77 M CHF, and current EBITDA margin is 47.42%. See more stats in CATALYST PHARMACEU financial statements.
Like other stocks, CN2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CATALYST PHARMACEU stock right from TradingView charts — choose your broker and connect to your account.